Navigation Links
Orexigen Therapeutics to Present at the Jefferies 2012 Global Healthcare Conference
Date:5/31/2012

SAN DIEGO, May 31, 2012 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX) today announced that management will present a company overview at the Jefferies 2012 Global Healthcare Conference in New York. The presentation is scheduled for Wednesday, June 6th at 9:30 a.m. EDT at the Grand Hyatt New York. To listen to the live webcast or a replay of the presentation, please visit the Investor Relations section of the Company's website at www.orexigen.com. A replay will be available for 14 days after the event.

About Orexigen® Therapeutics Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead product candidate is Contrave®, which has completed Phase III clinical trials and for which a New Drug Application has been submitted and reviewed by the FDA. The Company has also reached agreement with the FDA on a Special Protocol Assessment for the Contrave cardiovascular outcomes trial which the company plans to initiate this quarter. The Company's other product candidate, Empatic™, has completed Phase II clinical trials. Further information about the Company can be found at www.orexigen.com

Orexigen Contact:

Media Contact:  McDavid Stilwell

Denise PowellVP, Corporate Communications and Business Development

WCG(858) 875-8629

(510) 703-9491


'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Orexigen(R) Initiates Second Phase IIb Empatic(TM) Trial on Schedule
2. Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R)
3. Orexigen(R) Therapeutics Announces Changes to Its Clinical Programs and Management Team
4. Orexigen(R) Therapeutics Schedules July 20, 2009 Teleconference and Webcast Discussion of Contrave(R) Phase 3 Results
5. Orexigen(R) Therapeutics Schedules September 30, 2009 Teleconference and Webcast to Discuss Phase 2b Trial Results From Second Obesity Drug Candidate, Empatic(TM)
6. Orexigen(R) Therapeutics Releases New Efficacy Data for Contrave(R) in Late Breaker Presentations at the 27th Annual Scientific Meeting of The Obesity Society
7. Orexigen(R) Therapeutics Announces Third Quarter 2009 Financial Results
8. Orexigen(R) Therapeutics to Speak at Lazard Capital Markets Healthcare Conference
9. Orexigen(R) Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635
10. Orexigen(R) Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
11. Orexigen(R) Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/31/2015)...  Frequentz Inc., a global leader and champion of ... help the pharmaceutical industry understand the current and future ... (DSCSA). The white paper, "From Lot-based to Serialization-based Traceability", ... Standard(s) and Implementation Plan rollout, as well as ... that need to occur between now and the 2017 ...
(Date:3/31/2015)... 2015 Medela has announced the addition ... ® Motion™-Endure personal pumps to its Negative Pressure ... These new devices, along with the Invia ® ... provide innovative, high-quality NPWT solutions, designed to provide ... "We are happy to be able ...
(Date:3/31/2015)... PGI has announced an expansion of its ... at its San Luis Potosi, ... expansion is centered on solving the challenge of complicated ... personal care product manufacturers. The planned ... and packaging, will allow customers to take advantage of ...
Breaking Medicine Technology:Frequentz Releases White Paper Addressing DSCSA's Current & Future Impact 2Frequentz Releases White Paper Addressing DSCSA's Current & Future Impact 3Medela Launches Product Line to Support Individualized Care For Negative Pressure Wound Therapy Patients 2PGI Expands Manufacturing Capabilities At Mexico Plant 2
... Sept. 29, 2011 The U.S. Food and Drug ... the International Internet Week of Action (IIWA), a cooperative ... and illegal medical products. (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO ... between Sept. 20 and Sept. 27 is called OPERATION ...
... Sept. 29, 2011 CIVCO ... installed at the Instituto Radioterapia del Este in Puerto ... the Protura system elevates the level of radiation therapy ... need for many patients to travel for treatment. ...
Cached Medicine Technology:FDA Participates in Global Efforts to Protect Consumers and Patients from Unsafe Drugs on the Internet 2FDA Participates in Global Efforts to Protect Consumers and Patients from Unsafe Drugs on the Internet 3FDA Participates in Global Efforts to Protect Consumers and Patients from Unsafe Drugs on the Internet 4CIVCO's Protura™ Installed at Puerto Rico's Instituto Radioterapia del Este 2CIVCO's Protura™ Installed at Puerto Rico's Instituto Radioterapia del Este 3
(Date:3/31/2015)... (PRWEB) March 31, 2015 Due ... started to hire more caregivers, staffing personnel, and ... and care managers within the Greater Los Angeles ... training institution, 1Heart Caregiver University has firmed up ... its mission to provide quality in-home care through ...
(Date:3/31/2015)... Over the last several years, many improvements ... yielded better results and more efficient procedures. Similarly, the ... a good hair transplant surgeon, has resulted in astonishingly ... restoration have improved the efficiency of hair restoration procedures, ... precision and flexibility to the field of hair restoration. ...
(Date:3/31/2015)... 2015 In honor of National ... advice for buying from a NMEDA QAP certified ... is a nonprofit organization that provides consumer guidance ... and installation of mobility equipment. The organization’s Quality ... that consistently adhere to the highest quality safety ...
(Date:3/31/2015)... FL (PRWEB) March 31, 2015 Medical ... America, has met all criteria for Laboratory Accreditation by ... given only to laboratories that apply rigid standards of ... performance of proficiency testing, and pass a rigorous on-site ... COLA accreditation as a result of a long-term commitment ...
(Date:3/31/2015)... The Walk a Mile Project, as part of ... kicked off their 3rd research sequence. The new sequence ... Equivalence was and is a massive component of GMO ... Change The World Films. “We started our research by ... entered our food supply, just to get a bird's eye ...
Breaking Medicine News(10 mins):Health News:1Heart Ends 1st Quarter of the Year With 1Heart Caregiver University Training of New Staff and Commits To Provide More Jobs For Year 2015 2Health News:1Heart Ends 1st Quarter of the Year With 1Heart Caregiver University Training of New Staff and Commits To Provide More Jobs For Year 2015 3Health News:Beverly Hills Hair Transplant Surgeon Now Combines Advanced Robotic Hair Transplantation and Manual Techniques for Greatest Results 2Health News:Advanced Driving Systems Celebrates National Disability Month 2Health News:Local Medical DNA Labs, LLC. Recognized for Quality Laboratory Services 2Health News:The Walk a Mile Project Launches New Research Sequence on Substantial Equivalence of GMOs 2
... Lynne Eldridge, M.D., author,of Avoiding Cancer One Day At ... common forms of cancer during a series of FREE seminars ... in downtown San Jose on,Sunday October 28th between 10am and ... the tech museum you can also visit the,amazing Body Worlds ...
... the University at Buffalo,s Research Institute on Addictions (RIA) ... technique often used in behavioral medicine for stress reduction ... of alcohol use disorders. , ... reduction or MBSR in alcoholism treatment, we hope to ...
... cut with more testing and early detection, , , FRIDAY, ... women think that if there,s no family history of ... new survey found. , In fact, most people who ... to the American College of Obstetricians and Gynecologists (ACOG), ...
... Oct. 26 Peak International Limited,(Nasdaq: PEAK ) ... fiscal year 2008 ended September 30, 2007 will be ... A conference call to,discuss the results of the quarter ... 2007 at 10:00 AM ET. To access the ...
... third quarter financial results -, LAVAL, QC, Oct. ... announced that it will host a conference call on,Friday, ... its third quarter,2007 financial results. Labopharm will report its ... 7:00 a.m. the same day. To access the ...
... by Truth Wins Out:, What: The National Association ... annual meeting at the Dallas/Ft. Worth,Airport Marriott on October ... heterosexuals with a homosexual problem." A coalition of local ... 11AM, followed,by a demonstration against this controversial fringe group ...
Cached Medicine News:Health News:Author Reveals How to Cancer Proof Your Life on October 28th 2Health News:Dealing with stress as a treatment for alcohol abuse 2Health News:Survey Finds Many Women Misinformed About Cancer 2Health News:Survey Finds Many Women Misinformed About Cancer 3Health News:Peak International Sets Time for Discussion of Second Quarter Fiscal 2008 Financial Results 2Health News:Labopharm to host conference call Friday, November 9, 2007 at 8:30 a.m. (ET) 2Health News:Major Protest On Saturday Against Fringe Therapists Who Claim to 'Cure' Gays 2
... Delta Specialty / Drug Clinical System ... can consolidate Drugs of Abuse, TDM's ... thyroid, HbA1c and lipids in one ... a level of automation and flexibility ...
The Rheumatoid Factor (RF) assay is used for the quantitative analysis of rheumatoid factor in human serum....
Rheumatoid Factor , R1: 4 X 20 ml buffer, R2: 2 X 8 ml antibody, Test / Kit: 320 (H717)...
EXTEND is an absorbable synthetic punctal implant that provides occlusion up to three months. It is packaged 20 implants per box in sizes of .0.3mm, 0.4mm, 0.5mm. A variety pack in also available w...
Medicine Products: